Hosted on MSN1mon
Boehringer Ingelheim opens $66.8m new cancer research facility
Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The building is named after Angelika ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...
pharmaphorum5d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
VentureBeat1mon
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
–(BUSINESS WIRE)–October 9, 2024– Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-class ...
FierceBiotech29d
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
Yahoo Finance20d
Boehringer Ingelheim Expands Research and Development in Athens, Georgia
With a capital investment of $66.1 million and 63 new jobs created ... U.S. Animal Health Country Managing Director at Boehringer Ingelheim. "Each year, we invest nearly 12 percent of our sales ...